Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Adrian Bot at al. published in Nature Reviews Drug Discovery:
“In vivo CAR-T cell therapy is redefining the future of cellular immunotherapy!
While traditional CAR-T has revolutionized outcomes in hematologic malignancies, its use remains limited by complex manufacturing and logistics.
Now, in vivo CAR-T engineering — where CAR-T cells are generated directly inside the patient — offers a scalable, efficient, and potentially safer path forward.
Recent advances in RNA medicines, viral vectors, and nanotechnology are driving this innovation, showing early clinical success and expanding possibilities beyond blood cancers — even into autoimmune diseases like systemic lupus erythematosus.”
Title: In vivo chimeric antigen receptor (CAR)-T cell therapy
Authors: Adrian Bot, Andrew Scharenberg, Kevin Friedman, Lin Guey, Robert Hofmeister, James I. Andorko, Michael Klichinsky, Frank Neumann, Jagesh V. Shah, Andrew J. Swayer, Kyle Trudeau, Drew Weissman, Matthias T. Stephan, Christian J. Buchholz, Carl H. June
Read the Full Article on Nature Reviews Drug Discovery
More posts featuring Yan Leyfman.